PTC Therapeutics (PTCT) Scheduled to Post Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) will release its earnings data after the market closes on Thursday, April 25th. Analysts expect PTC Therapeutics to post earnings of ($1.31) per share for the quarter. PTC Therapeutics has set its FY 2024 guidance at EPS.Persons interested in registering for the company's earnings conference call can do so using this link.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.29 by ($0.53). The business had revenue of $307.06 million for the quarter, compared to analyst estimates of $315.90 million. On average, analysts expect PTC Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

PTC Therapeutics Price Performance

Shares of NASDAQ PTCT traded down $0.47 during mid-day trading on Thursday, hitting $24.69. 820,086 shares of the company's stock traded hands, compared to its average volume of 935,098. The company's 50-day moving average is $28.09 and its two-hundred day moving average is $25.60. The company has a market capitalization of $1.89 billion, a P/E ratio of -2.99 and a beta of 0.67. PTC Therapeutics has a 1 year low of $17.53 and a 1 year high of $59.84.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, Director Allan Steven Jacobson sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $27.38, for a total value of $273,800.00. Following the completion of the sale, the director now directly owns 12,348 shares in the company, valued at $338,088.24. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 12,256 shares of company stock worth $335,865 over the last three months. Corporate insiders own 5.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV purchased a new position in shares of PTC Therapeutics in the fourth quarter worth $43,000. Lazard Asset Management LLC raised its holdings in shares of PTC Therapeutics by 115.1% during the fourth quarter. Lazard Asset Management LLC now owns 2,478 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 1,326 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of PTC Therapeutics during the second quarter worth $161,000. Tower Research Capital LLC TRC raised its holdings in shares of PTC Therapeutics by 179.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,648 shares of the biopharmaceutical company's stock worth $183,000 after purchasing an additional 4,272 shares during the last quarter. Finally, Two Sigma Securities LLC purchased a new position in shares of PTC Therapeutics during the first quarter worth $207,000.

Analysts Set New Price Targets

PTCT has been the topic of several recent research reports. Jefferies Financial Group upped their target price on shares of PTC Therapeutics from $33.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, March 20th. Royal Bank of Canada increased their price objective on shares of PTC Therapeutics from $22.00 to $28.00 and gave the stock a "sector perform" rating in a research report on Friday, March 1st. TD Cowen reduced their price objective on shares of PTC Therapeutics from $32.00 to $30.00 and set a "market perform" rating on the stock in a research report on Friday, March 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price objective on shares of PTC Therapeutics in a research report on Friday, April 12th. Five equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $33.53.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.